Bridge City Capital’s Pacira BioSciences PCRX Stock Holding History

Bridge City Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.92M	Sell	312,297 -90,468	-22%	-$2.14M	1.81%	12
2026 Q1	$9.1M	Buy	402,765 +117,272	+41%	+$2.61M	2.52%	6
2025 Q4	$7.39M	Sell	285,493 -25,951	-8%	-$617K	2.17%	5
2025 Q3	$8.03M	Buy	311,444 +141,771	+84%	+$3.48M	2.14%	4
2025 Q2	$4.06M	Sell	169,673 -2,473	-1%	-$62.3K	1.14%	31
2025 Q1	$4.28M	Sell	172,146 -57,050	-25%	-$1.37M	1.28%	27
2024 Q4	$4.32M	Sell	229,196 -2,019	-0.9%	-$35.4K	1.15%	30
2024 Q3	$3.48M	Buy	231,215 +146,359	+172%	+$2.5M	0.96%	42
2024 Q2	$2.43M	Buy	84,856 +22,912	+37%	+$652K	0.82%	49
2024 Q1	$1.81M	Buy	+61,944	New	+$1.9M	0.66%	79

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bridge City Capital's PCRX Position: Q2 2026 in Review

Bridge City Capital reduced its Pacira BioSciences (PCRX) stake by 22% in Q2 2026, selling an estimated $2.14M and leaving 312,297 shares worth $7.92M. The position accounts for 1.81% of the portfolio, ranked #12.

Bridge City Capital first reported a position in PCRX in Q1 2024 and has held it in 10 quarters since. The position peaked at $9.1M in Q1 2026. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Bridge City Capital held 312,297 shares of Pacira BioSciences worth $7.92M as of Q2 2026.
Bridge City Capital sold 90,468 Pacira BioSciences shares in Q2 2026, an estimated $2.14M.
Pacira BioSciences made up 1.81% of Bridge City Capital's portfolio in Q2 2026, its #12 holding.
Bridge City Capital first reported a position in Pacira BioSciences in Q1 2024 and has held it in 10 quarters since.
Bridge City Capital's Pacira BioSciences position peaked at $9.1M in Q1 2026.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Bridge City Capital's 13F filing for Q2 2026, filed 11 Aug 2026.